Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2019 Aug 29;8(1):91–101. doi: 10.1016/j.jaip.2019.06.044

FIGURE 3.

FIGURE 3.

Patients achieving success in ISGA with crisaborole in AD-301 and AD-302. Kaplan-Meier analysis shows that patients treated with crisaborole achieved the studies’ primary endpoint (of clear [0] or almost clear [1] and a ≥2-grade improvement from baseline on the ISGA) sooner than did those treated with vehicle ointment (P <.001). AD, Atopic dermatitis; ISGA, Investigator’s Static Global Assessment. (Reprinted from Paller et al with permission from Elsevier.54)